|
|
|
Insider
Information: |
Sarena Francis Willard |
Relationship: |
President and COO |
City: |
Redwood City |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
5,756 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$14,217 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
5,756 |
|
|
Total
Value |
$14,217 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
![](../../../Gifs/iconPlus.jpg) |
PDL Biopharma Inc |
PDLI |
VP/Gen Counsel/Secy |
2008-09-15 |
5,756 |
|
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Five Prime Therapeutics Inc |
FPRX |
Chief Strategy Officer |
2021-04-16 |
0 |
2021-04-16 |
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Apexigen Ord Shs |
APGN |
President and COO |
2023-08-23 |
0 |
2022-10-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2016-11-25 |
4 |
AS |
$60.48 |
$1,281,511 |
D/D |
(21,189) |
81,266 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2016-11-23 |
4 |
AS |
$60.23 |
$810,997 |
D/D |
(13,465) |
81,266 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2016-11-28 |
4 |
AS |
$60.14 |
$102,839 |
D/D |
(1,710) |
81,266 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2017-01-03 |
4 |
D |
$48.60 |
$118,681 |
D/D |
(2,442) |
78,824 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2017-01-18 |
4 |
AS |
$47.39 |
$172,310 |
D/D |
(3,636) |
78,824 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2017-03-01 |
4 |
D |
$44.77 |
$885,730 |
D/D |
(19,784) |
75,118 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
EVP, Gen Counsel and Secretary |
|
2016-09-01 |
4 |
D |
$44.74 |
$875,472 |
D/D |
(19,568) |
74,266 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
EVP, Gen Counsel and Secretary |
|
2016-03-30 |
4 |
AS |
$40.01 |
$222,056 |
D/D |
(5,550) |
83,834 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
EVP, Gen Counsel and Secretary |
|
2016-03-29 |
4 |
AS |
$40.00 |
$178,000 |
D/D |
(4,450) |
83,834 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2021-04-16 |
4 |
D |
$38.00 |
$6,439,784 |
D/D |
(169,468) |
0 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2021-04-16 |
4 |
D |
$38.00 |
$90,630 |
I/I |
(2,385) |
0 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
EVP, Gen Counsel & Secretary |
|
2016-01-27 |
4 |
AS |
$34.73 |
$1,056,609 |
D/D |
(30,000) |
83,570 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2017-03-01 |
4 |
D |
$34.34 |
$107,519 |
D/D |
(3,131) |
71,987 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2021-02-24 |
4 |
D |
$25.71 |
$131,121 |
D/D |
(5,100) |
126,244 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2021-02-25 |
4 |
D |
$23.08 |
$38,151 |
D/D |
(1,653) |
124,591 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2021-02-26 |
4 |
D |
$22.23 |
$25,742 |
D/D |
(1,158) |
123,433 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2020-11-11 |
4 |
D |
$18.00 |
$198,018 |
D/D |
(11,001) |
116,010 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2020-12-11 |
4 |
D |
$16.14 |
$186,950 |
D/D |
(11,583) |
126,427 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2018-09-01 |
4 |
D |
$14.00 |
$39,340 |
D/D |
(2,810) |
76,177 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2018-09-28 |
4 |
D |
$13.92 |
$13,280 |
D/D |
(954) |
77,145 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2019-02-26 |
4 |
D |
$11.95 |
$14,268 |
D/D |
(1,194) |
82,955 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Chief Strategy Officer |
|
2019-02-05 |
4 |
D |
$11.43 |
$34,244 |
D/D |
(2,996) |
74,149 |
0 |
- |
|
PDLI |
PDL Biopharma Inc |
VP/Gen Counsel/Secy |
|
2008-09-15 |
4 |
D |
$10.84 |
$5,810 |
D/D |
(536) |
5,756 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
EVP, Gen Counsel and Secretary |
|
2016-03-29 |
4 |
OE |
$8.49 |
$37,781 |
D/D |
4,450 |
88,284 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
EVP, Gen Counsel and Secretary |
|
2016-03-30 |
4 |
OE |
$8.49 |
$47,120 |
D/D |
5,550 |
89,384 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|